Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Telomir Pharmaceuticals, Inc. reported a net loss of $(990,947) with no revenue for Q1 2026, an improvement from a $(2,179,828) loss in Q1 2025. Diluted EPS was $(0.03), better than $(0.07) a year earlier. The FDA cleared an IND for Telomir-1 to begin trials for advanced triple-negative breast cancer. A merger with TELI consolidated global rights to Telomir-1. Bayshore Trust committed up to $5.0M for funding, with $1.0M tied to IND acceptance. Cash is sufficient to fund operations into Q1 2027.
Telomir Pharmaceuticals, Inc. reported a first-quarter 2026 net loss of $(990,947) and no revenue as the company continues preclinical and early clinical preparations; diluted loss per share was $(0.03), improved from $(0.07) a year earlier, and cash is sufficient to fund operations into Q1 2027.
Financial Highlights
- Revenue was $0 for Q1 2026, unchanged from $0 in the year-ago quarter.
- Net income was a loss of $(990,947) for Q1 2026, compared with a loss of $(2,179,828) in Q1 2025 (loss narrowed by 54.5%).
- Diluted EPS was a loss of $(0.03) for Q1 2026, compared with $(0.07) in Q1 2025.
Business Highlights
- Clinical milestone: The FDA cleared an IND for Telomir-1 (Telomir‑Zn) to begin a trial in advanced/metastatic triple-negative breast cancer (TNBC).
- Pipeline consolidation: A merger with TELI unified global rights to Telomir‑1, simplifying development and potential commercialization.
- Capital & development funding: Bayshore Trust committed up to $5.0M, with $1.0M provided tied to IND acceptance and the start of a Phase 1/2 trial.
- R&D progress: Increased research and development spending and ongoing preclinical work to prepare for clinical trials across multiple indications.
- Operational runway: Reported cash supports operations into Q1 2027, enabling near-term clinical and regulatory activities.
Original SEC Filing: Telomir Pharmaceuticals, Inc. [ TELO ] - 10-Q - May. 14, 2026